ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Completes Placement and Entitlement Offer
|
|
gavint66
|
154 |
50K |
5 |
15/03/24 |
15/03/24 |
ASX - By Stock
|
154
|
50K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
gavint66
|
549 |
182K |
0 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
549
|
182K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
gavint66
|
549 |
182K |
3 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
549
|
182K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
gavint66
|
549 |
182K |
2 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
549
|
182K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
gavint66
|
549 |
182K |
4 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
549
|
182K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
gavint66
|
549 |
182K |
3 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
549
|
182K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
gavint66
|
549 |
182K |
2 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
549
|
182K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
gavint66
|
549 |
182K |
7 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
549
|
182K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
gavint66
|
5.5K |
2.7M |
7 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
5.5K
|
2.7M
|
7
|
|
ASX - By Stock
|
CYP |
Re:
Going forward...
|
|
gavint66
|
2.1K |
695K |
0 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
2.1K
|
695K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
gavint66
|
17K |
6.8M |
7 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
17K
|
6.8M
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
gavint66
|
549 |
182K |
0 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
549
|
182K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
gavint66
|
549 |
182K |
8 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
549
|
182K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
gavint66
|
549 |
182K |
0 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
549
|
182K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
gavint66
|
877 |
371K |
1 |
10/03/24 |
10/03/24 |
ASX - By Stock
|
877
|
371K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
gavint66
|
877 |
371K |
4 |
10/03/24 |
10/03/24 |
ASX - By Stock
|
877
|
371K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
gavint66
|
877 |
371K |
6 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
877
|
371K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
gavint66
|
877 |
371K |
0 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
877
|
371K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
gavint66
|
10K |
3.0M |
3 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
10K
|
3.0M
|
3
|
|
ASX - By Stock
|
CYP |
Re:
Going forward...
|
|
gavint66
|
2.1K |
695K |
0 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
2.1K
|
695K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
MSB shareholder class action
|
|
gavint66
|
116 |
44K |
2 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
116
|
44K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
gavint66
|
877 |
371K |
1 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
877
|
371K
|
1
|
|
ASX - By Stock
|
CYP |
Re:
Ann: First Patient Treated in Phase 2 GvHD Trial
|
|
gavint66
|
61 |
12K |
1 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
61
|
12K
|
1
|
|
ASX - By Stock
|
CYP |
Re:
Ann: First Patient Treated in Phase 2 GvHD Trial
|
|
gavint66
|
61 |
12K |
0 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
61
|
12K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast Shareholder Class Action (VID268/2022) – Notice to Group Members
|
|
gavint66
|
168 |
102K |
8 |
03/03/24 |
03/03/24 |
ASX - By Stock
|
168
|
102K
|
8
|
|
ASX - By Stock
|
PNV |
Re:
Ann: Webcast Recording - 1H24 Results
|
|
gavint66
|
24 |
9.2K |
4 |
03/03/24 |
03/03/24 |
ASX - By Stock
|
24
|
9.2K
|
4
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Cynata Appoints New Chief Business Officer
|
|
gavint66
|
6 |
2.1K |
0 |
02/03/24 |
02/03/24 |
ASX - By Stock
|
6
|
2.1K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast Shareholder Class Action (VID268/2022) – Notice to Group Members
|
|
gavint66
|
168 |
102K |
7 |
02/03/24 |
02/03/24 |
ASX - By Stock
|
168
|
102K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Litigation Update
|
|
gavint66
|
86 |
34K |
2 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
86
|
34K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast 2024 Half Year Financial Results Webcast
|
|
gavint66
|
62 |
23K |
1 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
62
|
23K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Half Year Financial Results Presentation
|
|
gavint66
|
78 |
25K |
3 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
78
|
25K
|
3
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Cynata Appoints New Chief Business Officer
|
|
gavint66
|
6 |
2.1K |
0 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
6
|
2.1K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Litigation Update
|
|
gavint66
|
86 |
34K |
3 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
86
|
34K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast 2024 Half Year Financial Results Webcast
|
|
gavint66
|
62 |
23K |
2 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
62
|
23K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast 2024 Half Year Financial Results Webcast
|
|
gavint66
|
62 |
23K |
4 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
62
|
23K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
AA
|
|
gavint66
|
13 |
4.8K |
7 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
13
|
4.8K
|
7
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Encouraging Initial Data from CYP-006TK DFU Trial
|
|
gavint66
|
49 |
10K |
0 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
49
|
10K
|
0
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Encouraging Initial Data from CYP-006TK DFU Trial
|
|
gavint66
|
49 |
10K |
0 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
49
|
10K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
AA
|
|
gavint66
|
13 |
4.8K |
1 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
13
|
4.8K
|
1
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Encouraging Initial Data from CYP-006TK DFU Trial
|
|
gavint66
|
49 |
10K |
0 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
49
|
10K
|
0
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Encouraging Initial Data from CYP-006TK DFU Trial
|
|
gavint66
|
49 |
10K |
0 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
49
|
10K
|
0
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Encouraging Initial Data from CYP-006TK DFU Trial
|
|
gavint66
|
49 |
10K |
0 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
49
|
10K
|
0
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Encouraging Initial Data from CYP-006TK DFU Trial
|
|
gavint66
|
49 |
10K |
0 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
49
|
10K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Partners with BMT CTN on Adult SR-aGVHD Trial
|
|
gavint66
|
362 |
121K |
0 |
25/02/24 |
25/02/24 |
ASX - By Stock
|
362
|
121K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
gavint66
|
10K |
3.0M |
1 |
24/02/24 |
24/02/24 |
ASX - By Stock
|
10K
|
3.0M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
gavint66
|
10K |
3.0M |
3 |
22/02/24 |
22/02/24 |
ASX - By Stock
|
10K
|
3.0M
|
3
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
gavint66
|
10K |
3.0M |
3 |
18/02/24 |
18/02/24 |
ASX - By Stock
|
10K
|
3.0M
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Grants Orphan Drug Designation for Revascor
|
|
gavint66
|
272 |
104K |
3 |
18/02/24 |
18/02/24 |
ASX - By Stock
|
272
|
104K
|
3
|
|